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Identifying individual differences of fluoxetine response in
juvenile rhesus monkeys by metabolite profiling
Y He1, CE Hogrefe2, D Grapov3, M Palazoglu3, O Fiehn3, CW Turck1 and MS Golub4
Fluoxetine is the only psychopharmacological agent approved for depression by the US Food and Drug Administration for children
and is commonly used therapeutically in a variety of neurodevelopmental disorders. Therapeutic response shows high individual
variability, and severe side effects have been observed. In the current study we set out to identify biomarkers of response to
fluoxetine as well as biomarkers that correlate with impulsivity, a measure of reward delay behavior and potential side effect of the
drug, in juvenile male rhesus monkeys. The study group was also genotyped for polymorphisms of monoamine oxidase A (MAOA),
a gene that has been associated with psychiatric disorders. We used peripheral metabolite profiling of blood and cerebrospinal
fluid (CSF) from animals treated daily with fluoxetine or vehicle for one year. Fluoxetine response metabolite profiles and
metabolite/reward delay behavior associations were evaluated using multivariate analysis. Our analyses identified a set of plasma
and CSF metabolites that distinguish fluoxetine- from vehicle-treated animals and metabolites that correlate with impulsivity. Some
metabolites displayed an interaction between fluoxetine and MAOA genotype. The identified metabolite biomarkers belong to
pathways that have important functions in central nervous system physiology. Biomarkers of response to fluoxetine in the normally
functioning brain of juvenile nonhuman primates may aid in finding predictors of response to treatment in young psychiatric
populations and in progress toward the realization of a precision medicine approach in the area of neurodevelopmental disorders.
Translational Psychiatry (2014) 4, e478; doi:10.1038/tp.2014.116; published online 4 November 2014
INTRODUCTION
Developmental childhood disorders such as attention deficit
hyperactivity disorder, autism, mental retardation and cerebral
palsy are frequently treated with antidepressant drugs of the
selective serotonin reuptake inhibitor (SSRI) type to control
behavioral symptoms.1–10 While short-term efficacy and toxicity
have been extensively studied, little is known about long-term
consequences of SSRI drug treatment in children and adolescents
especially as they relate to brain development.
Rodent studies have demonstrated that while acute fluoxetine
treatment has antidepressant effects,11 chronic treatment of the
animals during early life increases depressive- and anxiety-like
behaviors in adulthood.12–17 It is therefore conceivable that
antidepressant drugs can have profound effects on brain
developmental events that become apparent later in adulthood.
Concerns about long-term consequences of SSRI treatment
were initially raised in a subset of patients suffering from major
depressive disorder where the drugs caused undesired and
sometimes severe side effects including suicidality (suicidal ideas
or behavior).18–20 Already in 1991 the US Food and Drug
Administration was made aware of concerns that the SSRI
fluoxetine, marketed as Prozac, was causing suicidal behaviors
that occurred right at the onset of treatment. Similar observations
were also obtained for other antidepressants including amitripty-
line and paroxetine. Treatment-emergent suicidal ideation in
response to SSRI treatment21–26 was later confirmed by a meta-
analysis,27 which prompted the US Food and Drug Administration
to issue a black-box warning for several SSRIs including fluoxetine.
This warning was particularly directed toward SSRI treatment of
children and adolescents.28
The immediate pharmacological action of SSRIs is an increase of
monoamine levels in the synaptic cleft. However, the emergence
of therapeutic effects in patients takes 4–6 weeks of daily
treatment.29 Before that many patients show decreased psycho-
motor retardation along with increased energy levels, but still
suffer from the typical major depressive disorder symptoms of low
self-esteem, worthlessness and guilt. This combination of symp-
toms can lead to a disinhibitory effect and an increased risk of
suicidality. Other clinical symptoms that have been associated
with suicidality in response to antidepressant treatment include
insomnia, akathisia and panic attacks.18 Reports on the identifica-
tion of reliable treatment-emergent suicidal ideation predictors or
risk factors able to identify patient subgroups experiencing
adverse side effects have been scarce. In one study patients with
treatment-emergent suicidal ideation were compared with
patients without increase in suicidal ideation and a subgroup
that never reported suicidal ideation.30 Although the study was
carried out with small cohort numbers, the results indicated that a
combination of genetic markers may be able to classify treatment-
emergent suicidal ideation patients.
As mentioned above, consequences for brain development are
a major concern of long-term treatment with fluoxetine. This does
not only apply to fetal exposure but also to children and
adolescents subjected to antidepressant treatment.31 Adverse
consequences that can affect behavior, cognitive abilities and
emotion may result from chronic exposure to antidepressants and
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psychotropic drugs in early life. In addition, the drugs can
potentially lead to structural central nervous system (CNS)
alterations with unknown consequences on behavior in adult-
hood, a phenomenon known as neuronal imprinting. In light of
the adverse effects that were observed in children taking
antidepressants, it is critical to obtain improved clinical parameters
that can help the physician with treatment. Biosignatures can be
of great value not only for predicting therapeutic response to the
drug but also in the delineation of pathways affected by the drug.
Similar to humans, rhesus monkeys have a prolonged stage of
juvenile development between infancy and puberty and are
therefore considered a good model to study long-term SSRI
effects. The animals also have many polymorphisms in genes that
have been associated with psychiatric disorders in humans.
Metabolites that reflect pathway activity, also referred to as
‘Authentic Biomarkers’, provide a metric for predicting treatment
response and undesired side effects.
Several recent studies have utilized metabolomics, a method to
study a great number of metabolites, to interrogate psychiatric
drug treatment effects. Atypical antipsychotic treatment influ-
enced the metabolism of specific lipid classes in patients with
schizophrenia.32 Metabolomic studies on treatment effects of
traditional Chinese medicine in rats identified potential biomarker
candidates.33,34 In another study a pharmacometabolomic
approach was used to guide targeted pharmacogenomic analyses
in antidepressant responders versus nonresponders.35 A pilot
study in depressed patients of old age revealed alterations in
plasma metabolite levels of GABA, glycerol and several fatty acids
compared with controls36 with many of the alterations normalized
after remission.
Similar to fluoxetine the SSRI paroxetine inhibits presynaptic
serotonin transporters leading to enhanced serotonergic synaptic
transmission, which was previously shown to be essential for
therapeutic efficiency.37 We have results from a metabolomics
analysis in DBA/2Ola mice that enhanced serotonin availability
resulting from chronic paroxetine treatment that leads to diverse
downstream pathway alterations.38 Pathways affected by parox-
etine treatment were directly or indirectly related to energy
metabolism and included glycolysis, amino acid metabolism and
hormone signaling. Mitochondrial dysfunction including energy
metabolism has been repeatedly reported in neuropsychiatric
disorders.39 Importantly, a comparison of CNS with blood plasma
metabolite alterations identified several metabolites as biomarker
candidates for the assessment of paroxetine treatment effects in
the periphery.38
In the current study we have examined the long-term effects of
fluoxetine in juvenile male rhesus monkeys, an animal with brain
functions similar to humans that differ in two common gene
polymorphisms for monoamine oxidase A (MAOA) activity.
Animals were of the same age, housed under controlled
conditions and fed an identical diet. Despite being an outbred
population this improves the signal-to-noise ratio of the drug-
elicited metabolite level changes as well as statistical analyses,
thereby aiding the discovery of pathways affected by drug
treatment.
We used metabolite profiling data obtained from plasma and
cerebrospinal fluid (CSF) to identify biomarkers of pharmacologi-
cal response and biomarkers that are associated with impulsivity
behavior during childhood after 1 year of fluoxetine treatment.
Brain-derived metabolites are more abundant and hence easier to
detect in CSF compared with blood where metabolites from many
other body organs are present. Still, brain-derived metabolites can
be detected in blood, albeit using the more sensitive targeted
metabolomics approach.
To compare fluoxetine’s metabolic profile and behavioral
effects, we used a reward delay test. The most common reward
delay test used in children, reward devaluation, is associated with
parent and teacher ratings of self-control and with the
temperament trait conscientiousness,40 predicts later impulse
control, achievement and competence into adolescence,41,42 and
is associated with location and complexity of neural networks.42–44
Poor performance on reward delay tests is commonly interpreted
as impulsivity, or a deficit in response inhibition. Another potential
interpretation has to do with reward valence, or the experienced
value of the reward, with increased reward value leading to
premature responses.40,45
The identification of predictors/biosignatures of side effects is
critical for pediatric psychiatry by enabling the physician to initiate
preventive interventions in patients suffering from childhood
disorders with behavioral components. Prediction of response to
treatment will be valuable in childhood pharmacotherapy to
optimize therapeutic response and minimize adverse side effects.
Ultimately it is hoped that the metabolite biomarkers will aid in
stratifying patients by correlating them with genetic and
behavioral data. Affected pathway information will improve our
understanding of adverse effects caused by fluoxetine in children.
MATERIALS AND METHODS
Assurance of compliance with animal codes
All procedures followed the Guide for the Care and Use of Laboratory
Animals of the National Research Council. The CNPRC (California National
Primate Research Center) is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care. Protocols for this project
were approved before implementation by the UC Davis Institutional
Animal Care and Use Committee.
Animals and animal care
Male rhesus monkeys (Macaca mulatta) approximately 1 year of age were
selected from the colony at the CNPRC to form a cohort balanced for age,
health history, infant stress responsiveness as evaluated routinely at
3 months of age, and genetic polymorphism of MAOA and 5HTTLPR genes,
which affect serotonin-mediated brain functions. Genotyping for MAOA
variable number tandem repeat (VNTR) polymorphisms was conducted by
the UC Davis Veterinary Genetics Laboratory using PCR with forward and
reverse primers. The male infants in our study were identified as
hemizygous for low transcribing (7 VNTR) or high transcribing (4, 5 or 6
VNTR) polymorphisms.46 The animals were transferred to an indoor cage
room and housed in double cages that allowed socialization in pairs. The
cages were arranged to the right and left sides of a central area of the cage
room and in two vertical tiers. On the basis of experience, MAOA genetic
polymorphism was included in the design of the study and cage location
variables were screened as potential covariates in data analyses.
All subjects received identical, standardized husbandry and enrichment
according to CNPRC protocols. Routine husbandry included a 12 h light
cycle, daily cleaning of cages and replacement with sterilized cages at
2 week intervals, feeding of commercial diet twice daily, enrichment with
play objects inside the cage, mirrors on the outside of the cages and novel
food items provided on a regular schedule.
The juvenile monkeys were gradually adapted to dosing and behavioral
testing procedures. At the end of the first year of dosing, the impulsivity
test and sampling for metabolomic analysis reported here were
conducted. After 1 year of dosing, monkeys were assessed with the
behavioral impulsivity test (reward delay) to evaluate the side effects of
fluoxetine treatment on the behavior level. Blood and CSF specimens were
collected for metabolomics analysis.
Animal health was evaluated daily. No conditions resulting in veterinary
diagnosis were reported, with the exception of episodes of diarrhea
treated with Tylosin. Linear and ponderal growth were measured at
intervals throughout the study without indication of fluoxetine effects
during the dosing period (Supplementary Table 1).
Study design
Juvenile male rhesus monkeys with high- and low-activity MAOA
polymorphism genotypes (n= 16/MAOA polymorphism group) were
randomized within group to receive either fluoxetine or an equivalent
volume of vehicle (n= 16 per treatment group) as shown in Figure 1.
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Fluoxetine dosing
Fluoxetine dose selection was based on information in the human and
nonhuman primate literature and on a preliminary pharmacokinetic/
pharmacodynamic study to provide steady state circulating levels of
fluoxetine/norfluoxetine in the range reported for therapeutic use of
fluoxetine in children.47 Dosing was initiated at 1 year of age at 1.6
mg kg− 1 per day and adjusted to 2.4 mg kg− 1 per day after 11 months.
Liquid fluoxetine (20 mg per 5ml, Webster Veterinary) was prepared for
oral dosing by dilution in flavored commercial flavoring syrup (Torani).
Monkeys were trained to come to the front of the cage and receive the
dose from the end of a 6ml syringe, which was inserted into the cage. The
vehicle administration consisted of fluid with the same taste and volume.
Impulsivity test
To compare fluoxetine’s metabolic profile and behavioral effects, we used
a reward delay test adapted for monkeys (Supplementary Figure 1) from
similar tests in children to measure impulsivity.48,49 For the impulsivity test,
monkeys were relocated individually to a separate test room. The
impulsivity test was hand administered in the Wisconsin General Test
Apparatus in one session of 40 trials. For each trial, an opaque door was
raised revealing a test board consisting of a small preferred food treat
(raisin, miniature marshmallow) covered with a large transparent plastic
box behind an opaque plastic screen. The screen was moved back 1 inch
every 2 s for seven screen intervals until the box was fully disclosed, at
which point the monkey could displace the box and retrieve the reward. If
the monkey touched the screen or the box before the box was fully
disclosed the trial was terminated. The apical end point for analysis was the
number of screen intervals to complete the trial. Testing was blinded and
randomized for group.
Blood and CSF sampling
Venous blood samples for plasma extraction were collected after an
overnight fast under ketamine anesthesia (10mg kg− 1 intramuscular). The
anesthesia was then supplemented with dexmedetomidine (0.0075-0.015
mg kg− 1) for CSF collection, which was performed via the drip method
from the cisterna magna under sterile conditions.
Metabolite extraction
Plasma and CSF samples were extracted with 1 ml of − 20 °C isopropanol/
acetonitrile/water (IPA/ACN/H2O) (3/3/2, v/v/v ). Samples were mixed for
5 min at 4 °C using an Eppendorf Orbital Mixing Chilling/Heating plate
(Hauppauge, NY, USA) and 500 μl dried extracts were stored at − 80 °C. See
Supplementary Methods for details on metabolite measurements.
Statistical analysis
The design and analysis strategy are depicted in Figure 1. To identify
metabolite biomarkers in response to fluoxetine treatment, multivariate
linear regression model was applied and the metabolites with significant
intensity difference between vehicle- and fluoxetine-treated groups were
selected. We normalized the intensities of each metabolite to have a mean
of zero and a s.d. of one. MAOA genotype was added in the regression
analysis considering the treatment-by-genotype interaction. Regression
model was formulated as Intensity of Metabolite ~ Treatment ×Genotype.
Owing to the batch bias in the plasma metabolite profiling, batch was
added as a covariate. The significance level was set at P-valueo0.05.
The apical end point of the impulsivity test was analyzed by two-way
analysis of variance (GLM, JMP/SAS) using drug treatment and MAOA
genotype as the independent variables. In addition, background variables
were screened for association with this end point and included as
covariates when appropriate. The significance level was P-valueo0.05.
To identify metabolites that indicated the behavior-related side effect,
we used multivariate linear regression and calculated the coefficients
between the metabolite intensities and the impulsivity outcome (the
average screen interval). As the covariate cage tier (‘top/bottom’)
introduced bias in the behavioral outcome, we controlled the cage
location as a covariate variable in regression. In addition to the cage tier
effect, the batch bias in the plasma metabolite profiling was also
considered as a covariate in the regression for plasma metabolite profiling
data. All calculations were performed under the R statistical environment
(http://www.r-project.org/). Pathway analysis was conducted using Meta-
boAnalyst online pathway tool (http://www.metaboanalyst.ca).
RESULTS
Plasma and CSF metabolite profiling in response to fluoxetine
treatment
A total of 143 metabolites in plasma and 100 metabolites in CSF
with known identities were covered in the analysis. To explore the
global metabolite intensity differences among groups with
different treatment and genotype, a partial least square discrimi-
nant analysis was performed on the plasma and CSF metabolite
profiles. The partial least square discriminant analysis results
demonstrated separation of metabolite profiles between fluox-
etine- and vehicle-treated groups (Figure 2a) and separation
between high- and low-MAOA genotypes. CSF displayed a better
separation than plasma samples.
To identify metabolites that differ between fluoxetine and
vehicle treatments, multivariate linear regression analyses were
carried out for each metabolite. In plasma, we found 19
metabolites that showed significant intensity level differences
(P-value o0.05) between control and fluoxetine groups. Odds
ratios (ORs) and P-values are shown in Table 1. Among them,
twelve metabolites, for example, 5-aminovaleric acid lactam
(Figure 2b) and nicotinic acid presented higher intensity levels
and seven metabolites, for example, arachidonic acid showed
lower intensity levels in fluoxetine- compared with vehicle-treated
animals. On the basis of the regression on treatment-by-genotype
interaction, twenty-one metabolites displayed a significant inter-
action between fluoxetine and MAOA genotype, indicating that
they depend on both factors. Ten metabolites, including
arachidonic acid and hypoxanthine, showed lower intensity levels
in high-MAOA compared with low-MAOA monkeys in the
fluoxetine treatment group. An opposite trend was observed in
the control group. Eleven metabolites, including dehydroascorbic
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Figure 1. Study design and analysis strategy. (a) Study design.
Thirty-two juvenile male rhesus monkeys with high- and low-activity
MAOA genotypes were used in our study. At 1 year of age, animals
were randomized to receive either fluoxetine or an equivalent
volume of vehicle per day (n= 8 per group). After 1 year of dosing,
monkeys were assessed with impulsivity test to evaluate the
fluoxetine effect on the behavioral level and blood and cerebrosp-
inal fluid (CSF) specimens were collected for metabolomics analysis.
(b) Analysis strategy. To identify metabolite biomarkers for the
response to fluoxetine, multivariate linear regression model was
applied for plasma and CSF metabolite profiling data. Analysis of
variance was used to examine the difference of impulsivity
outcomes between fluoxetine-treated and control animals. To
identify metabolites associated with impulsivity, we performed
multivariate linear regression of the impulsivity outcomes (average
screen intervals) on the intensity of each metabolite in plasma and
CSF. MAOA, monoamine oxidase A.
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Figure 2. Plasma and CSF metabolites in response to fluoxetine treatment. (a) Partial least square (PLS) analysis demonstrates separation of
metabolite profiling between fluoxetine- (green) and vehicle-treated (red) monkeys in both plasma and CSF specimens. (b) Two metabolite
candidates that respond to fluoxetine treatment in both plasma and CSF. 5-aminovaleric acid lactam (left) displayed increased metabolite level
in fluoxetine-treated group. Hypoxanthine’s levels (right) are dependent on treatment-by-genotype interaction. The upper and lower borders
of the box represent the 25th and 75th percentile, respectively; the solid line represents the median; upper and lower whiskers are minimum
and maximum without outliers, respectively; points represent outliers. CSF, cerebrospinal fluid; MAOA, monoamine oxidase A.
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Figure 3. Fluoxetine increases juvenile rhesus monkey impulsivity. The number of screen intervals elapsing before the monkey responded
were averaged across 40 trials of the test session. Fluoxetine, but not MAOA genotype, influenced performance (P= 0.024). The upper and
lower borders of the box represent the 25th and 75th percentile, respectively; the solid line represents the median; upper and lower whiskers
are minimum and maximum without outliers, respectively. Points represent the average screen intervals across 40 trials of individual monkeys
in each group. MAOA, monoamine oxidase A.
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acid, showed the opposite pattern, higher intensity levels in
fluoxetine-treated high-MAOA monkeys versus low-MAOA mon-
keys, but with opposite trends in the control group.
In CSF we found that tryptophan, ribitol, 2-hydroxybutanoic
acid and isoheptadecanoic acid differed in intensity levels
between fluoxetine- and vehicle-treated animals. Isoheptadeca-
noic acid also presented a similar trend in plasma (ORs = 0.38 and
P-value = 0.055) and had a significantly lower intensity level in
fluoxetine- versus vehicle-treated animals in CSF (ORs = 0.31 and
P-value = 0.017). Moreover, 5-aminovaleric acid lactam displayed
an increased level in the fluoxetine group (ORs = 2.83 and P-
value = 0.035) and was also significantly different in plasma
(ORs = 3.09 and P-value = 0.024, Figure 2b). Taking treatment-by-
genotype interaction into consideration, three metabolites pre-
sented a significant interaction effect (Table 1). Two of them,
threitol and N-acetylmannosamine, displayed higher intensity
levels in high-MAOA monkeys compared with low-MAOA animals
of the fluoxetine-treated group, with an opposite direction in the
control group. For hypoxanthine for which we also found an
interaction in plasma (ORs = 4.13 and P-value = 0.048, Figure 2b),
we observed the same interaction trend in CSF (ORs = 4.92 and P-
value = 0.024).
Fluoxetine increased juvenile rhesus monkey’s impulsivity
The impulsivity test measures how long the monkey can wait to
receive the food reward by counting the screen intervals. Analysis
of variance demonstrated significant effect of fluoxetine on screen
interval with no significant effect of MAOA polymorphism and no
interaction (Figure 3). Cage position (top or bottom tier) was
identified as a covariate. The fluoxetine effect including cage
position covariate was significant by analysis of variance
(P= 0.024). This test indicated that fluoxetine treatment could
induce a high-impulsivity side effect in juvenile monkeys.
However, no significant difference between high- and low-
MAOA genotypes was observed.
Metabolites associated with impulsivity
As we observed the impulsivity side effect on juvenile monkeys
treated with fluoxetine for 1 year, we next investigated whether
blood or CSF metabolite levels can reflect this behavior. Simple
linear regression of the average screen interval on signal intensity
of each metabolite provided a test of association between
metabolite levels and impulsivity behavior. In plasma, we found
three metabolites (xylitol, sucrose, guanosine) that displayed a
negative association with the average screen interval (Table 2).
These were independent of the batch effect bias of the plasma
metabolite data and the cage tier.
In CSF we had not observed a batch effect for metabolite
profiling, so we regressed the average screen interval on the
intensity of each metabolite by only adding cage location as a
confounding variable. Five metabolites (xylitol, valine, pyruvic
acid, alanine) were found negatively associated with the behavior
outcome (Table 2) and the associations were independent of cage
location. The negative coefficients of these metabolites from our
models represent positive association between metabolite
changes in blood and CSF specimens and impulsivity level during
fluoxetine dosing.
Pathways affected by fluoxetine
To explore the biological function and pathways that were
affected by fluoxetine, we applied function annotation and
enrichment analysis on the metabolite candidates that we found
in plasma and CSF in response to fluoxetine treatment and
indicating impulsivity (Figure 4). Two pathways that are linked,
Table 1. Plasma and CSF metabolite odds ratios and P-values in
response to fluoxetine treatment
Metabolite Fluoxetine vs
vehicle
Fluoxetine-by-
MAOA interaction
Odds
ratio
P-value Odds
ratio
P-value
Plasma
Asparagine 4.22 0.002* 0.22 0.017*
Glyoxalureaa 3.20 0.004* 0.23 0.010*
Parabanic acida 2.46 0.012* 0.34 0.031*
Oxamic acid 3.37 0.014* 0.20 0.020*
Nicotinic acid 2.08 0.016* 0.43 0.044*
2,3-Dihydroxypyridine 2.42 0.030* 0.25 0.017*
Shikimic acid 2.52 0.030* 0.08 0.000*
Dehydroascorbic acid 2.81 0.036* 0.19 0.018*
5-Aminovaleric acid lactam 3.09 0.024* 0.43 0.213
Glycolic acid 2.49 0.029* 0.39 0.107
Urea 2.87 0.039* 0.40 0.194
2,3,5-Trihydroxypyrazinea 2.50 0.049* 1.00 0.997
Indole-3-lactate 0.31 0.014* 5.98 0.009*
Arachidonic acid 0.34 0.021* 6.21 0.007*
Myristic acid 0.34 0.031* 4.65 0.029*
Hydroxylamine 0.34 0.017* 3.38 0.052
N-acetyl-5-
hydroxytryptamine
0.34 0.035* 3.22 0.103
Palmitic acid 0.35 0.038* 4.07 0.052
Fructose 0.36 0.048* 3.75 0.067
3-Phosphoglycerate 2.17 0.098 0.13 0.003*
2-Deoxyerythritola 1.87 0.201 0.20 0.027*
Benzylalcohol 1.77 0.253 0.20 0.029*
Allantoic acid 0.46 0.104 6.29 0.009*
Cysteine 0.42 0.078 5.78 0.015*
Fumaric acid 0.71 0.475 5.27 0.019*
Linoleic acid 0.41 0.070 5.02 0.022*
Isoheptadecanoic acid 0.38 0.055 4.88 0.030*
2-Ketoisocaproic acid 0.64 0.366 4.24 0.045*
Hypoxanthine 0.58 0.275 4.13 0.048*
CSF
5-Aminovaleric acid lactam 2.83 0.035* 0.44 0.230
Isoheptadecanoic acid 0.31 0.017* 2.26 0.217
Tryptophan 0.32 0.025* 3.75 0.060
Ribitol 0.32 0.026* 3.27 0.092
2-Hydroxybutanoic acid 0.37 0.041* 3.16 0.094
Hypoxanthine 0.64 0.352 4.92 0.024*
Threitol 2.39 0.072 0.19 0.018*
N-acetylmannosamine 1.45 0.433 0.25 0.047*
Abbreviations: CSF, cerebrospinal fluid; MAOA, monoamine oxidase A.
aIdentified by NIST mass spectral library. *P = 0.04.
Table 2. Plasma and CSF metabolites associated with impulsivity
Metabolite Average screen interval P-value
Coefficients 95% CI (2.5%,
97.5%)
P-value Batch
effect
Cage
effect
Sucrosea −0.81 (−1.45, − 0.17) 0.029* 0.143 0.048*
Xylitola −0.91 (−1.65, − 0.18) 0.031* 0.746 0.043*
Guanosinea −1.37 (−2.55, − 0.18) 0.043* 0.128 0.111
Valineb −1.92 (−3.12, − 0.72) 0.008* — 0.109
Xylitolb −1.23 (−2.24, − 0.23) 0.032* — 0.061
Alanine 2b −1.38 (−2.59, − 0.17) 0.044* — 0.266
Pyruvic acidb −1.23 (−2.33, − 0.13) 0.047* — 0.768
Alanine 1b −1.36 (−2.57, − 0.14) 0.048* — 0.273
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid. aPlasma.
bCSF. *P = 0.04.
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‘Alanine, Aspartate, Glutamate’ metabolism (Figure 4a) and
‘Nicotinate, Nicotinamide’ metabolism (Figure 4b), were influ-
enced by fluoxetine treatment. Two metabolites, asparagine and
fumaric acid, responded to fluoxetine in plasma, and two
impulsivity indicators, alanine and pyruvic acid, were mainly
involved in ‘Alanine, Aspartate and Glutamate’ metabolism. For
‘Nicotinate, Nicotinamide’ metabolism, we found the impulsivity
indicator pyruvic acid and four other metabolites (nicotinic acid,
2,3-dihydroxypyridine, 2,3,5-trihydroxypyrazine, fumaric acid)
altered by fluoxetine as well as dependent on MAOA genotype.
Both pathways are of relevance for psychiatric phenotypes, either
containing metabolites with important functions in the CNS, such
as nicotinate and glutamate, or being linked to other pertinent
pathways that include neurotransmitters, such as serotonin in
tryptophan metabolism.
Monoamine metabolites were not assessed in the present
biomarker screening study but pilot work demonstrated that
14 weeks of dosing at 2 mg kg− 1 per day significantly increased
CSF serotonin and showed a trend for decrease of the serotonin
metabolite 5HIAA.47
DISCUSSION
Drugs that increase monoamine levels in the synaptic cleft are
used for the treatment of a variety of psychiatric diseases.
Fluoxetine is approved for the treatment of childhood
depression.4 Despite evidence that fluoxetine can have beneficial
effects in children affected by attention deficit hyperactivity
disorder, autism, mental retardation and cerebral palsy, a black-
label warning for the drug was issued by the US Food and Drug
Administration resulting from severe side effects in a subset of
patients. Initially on the basis of case reports on patients suffering
from major depressive disorder, these findings were later
corroborated by clinical trials in greater patient populations.18–20
As fluoxetine continues to be widely prescribed for psychiatric
diseases including children and adolescents, it is of utmost
importance to enable physicians to stratify and exclude patients
that may suffer from severe side effects. Biomarkers are critical to
achieve the goal of precision medicine, in this case by excluding
patients at high risk of developing side effects from fluoxetine
treatment. As psychiatric diseases are considered to be neurode-
velopmental disorders, antidepressant effects on brain develop-
ment need to be studied and understood to identify affected
pathways that in turn can reveal pertinent biomarker information.
Another study on the long-term effects of fluoxetine in juvenile
rhesus monkeys that was published recently50 found no
significant behavioral alterations following 1 year of treatment
with the drug. Impulsivity was not assessed. However, the authors
found an upregulation in the neocortex and hippocampus of the
serotonin transporter, but no 5-HT1A receptor expression
differences. Due to the limited sample size no conclusions could
be drawn with regard to adverse effects of fluoxetine treatment. In
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an extension of their studies the authors also separated monkeys
from their mothers at birth to simulate human childhood stress
but did not find any behavioral differences between fluoxetine
and vehicle-treated animals in adulthood.
We and others have used –omics technologies to identify
molecular pathways and biomarker candidates in rodents that
were treated chronically with an SSRI.38 In several of these studies,
behavioral effects including anxiety- and affective-like symptoms
in adult mice when treated with fluoxetine during adolescence
were found.12–17 Likewise, adult mice treated with fluoxetine
during adolescence showed altered depression-like behavior in
social interaction and forced-swim tests as well as anxiety-like
responses in the elevated plus maze. In one case these effects
mimicked behavior in 5-HTT knockout mice suggesting that
serotonin has a critical role in brain development by modulating
emotional behavior in the adult animals.51 In mice, SSRI treatment
has been shown to upregulate the expression of several genes
that are associated with neurogenesis, neuronal survival and
neuronal differentiation.52 When several inbred mouse strains
were compared, it was obvious that behavioral and neuronal
effects of chronic fluoxetine treatment were linked. Cell prolifera-
tion in the hippocampus was only observed in those mouse
strains that also showed a behavioral response to treatment.52
Although results from these studies have been very useful for
the identification of metabolic and signaling pathways affected by
SSRIs, rodents are arguably not the preferred species when it
comes to studying drug effects on brain development. Here
species closer in evolutionary development are more relevant for
the assessment of behavioral alterations associated with human
pathology.
In the present study we have used juvenile nonhuman primates
to identify biomarkers and molecular pathways affected by long-
term treatment with fluoxetine. This was achieved by a
hypothesis-free approach with the help of metabolomics analyses.
Metabolites can be considered a molecular correlate of the
phenotype of an organism. They are dynamic and their levels are
influenced by enzyme activities, protein–protein interactions and
protein posttranslational modifications. Although brain metabolite
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profiles would be most relevant for assessing pathway alterations,
peripheral fluids can be used as a proxy reflecting changes in the
CNS. They are also the only source that can be assessed for
eventual clinical translation.
In the current study we have used CSF and plasma from male
rhesus monkeys that differ in two common gene polymorphisms
for MAOA activity, treated with either fluoxetine or vehicle.
Environmental factors were excluded as best as possible with
animals receiving the same diet and housed under controlled
conditions, thus minimizing the signal-to-noise ratio. Due to the
fact that the macaques represent an outbred population, our
study is similar to a clinical investigation with patients.
On the basis of the metabolomics analyses we were able to
identify biomarkers for fluoxetine treatment response as well as
biomarkers that correlate with impulsivity, a measure of reward
delay behavior. Statistical analyses also took into account
polymorphisms of MAOA.
Blood and CSF are the most common sample types for
biomarker development for psychoactive agents. Though readily
available, blood has the disadvantage of multiple sources of
metabolites from different tissues and metabolic pathways.
Lumbar puncture for CSF collection is more specific, but it is a
rather invasive procedure and is not used in children for the
evaluation of response to treatment on a routine basis. Although
there is an exchange of blood and CSF, individual metabolite
abundances vary. This is due to the fact that although the brain is
the primary source for metabolites present in CSF, all body tissues
contribute to the blood metabolome which therefore tends to be
more complex. In addition to the qualitative metabolite differ-
ences between the two body fluids there are also quantitative
differences for an individual metabolite which can originate from
several body organs. Hence it is not surprising that our analyses
did not result in the same metabolite signatures for blood and CSF
(Tables 1 and 2). We only found two metabolites, 5-aminovaleric
acid lactam and hypoxanthine, whose levels were significantly
changed in both blood and CSF (Figure 2b). In future studies we
plan to specifically target all the identified CSF metabolites in the
blood which will allow us to identify and quantitate them in a
more sensitive manner. Ultimately, blood will be the preferred
body fluid that can be used as a source for a biosignature based
assay in children.
Interrogation of the metabolites with regard to pathways
revealed ‘Alanine, Aspartate, Glutamate’ metabolism and ‘Nicoti-
nate, Nicotinamide’ metabolism to be affected by fluoxetine
treatment. The pathways affected by fluoxetine treatment harbor
several metabolites that have important functions in CNS
physiology and have been implicated in psychiatric phenotypes.
Both pathways are connected by L-aspartate oxidase, an enzyme
that catalyzes the reaction of L-aspartate to iminoaspartate, the
first step in the de novo biosynthesis of NAD+.
Although monoamine deficiency is the most frequently
mentioned hypothesis for mood disorders, more recent evidence
suggests that the glutamatergic system is also involved in the
etiology.53,54 The free acid form of 5-aminovaleric acid lactam, one
of two metabolites whose levels were significantly affected in
both plasma and CSF, is a gamma-aminobutyric acid (GABA)
homolog and has been shown to be a weak GABA agonist,55
further implicating the glutamatergic system. We have preliminary
data from mice that indicate that SSRI treatment results in altered
glutamate levels in the hippocampus (Park et al., unpub-
lished). Furthermore, ‘Alanine, Aspartate, Glutamate’ metabolism,
is an important part of the energy metabolism that we and others
have found to be affected in several mouse models and upon SSRI
treatment.38
Nicotinamide, a precursor of the pathway leading to NAD+, has
been shown to have benzodiazepine-like anxiolytic activities and
is an endogenous GABA receptor ligand.56 ‘Nicotinate, Nicotina-
mide’ metabolism is also connected to tryptophan metabolism
which produces serotonin, the neurotransmitter whose concen-
tration in the synaptic cleft is most affected by the antidepressant
drug used in the current study.
We used metabolomics analyses to identify biomarker candi-
dates that are part of molecular pathways affected by fluoxetine
treatment. However, due to the small sample size (n= 16 per
group) in comparison with the number of analyzed metabolites
tested in our study (approximately 100) the biomarker candidates
could not reach the Bonferroni level. In addition, because these
studies were conducted in normally functioning brains of the
juvenile monkeys, generalization of the significance of these
pathways for neurodevelopmental disorders in children will
require further studies. Time course analyses are needed to assess
the metabolite signature with regard to its potential to serve as a
treatment response biomarker. Although the biomarker candi-
dates may not necessarily underlie neurodevelopmental etiology,
they could provide diagnostic readouts for treatment of juvenile
patients. If confirmed, the identified molecular pathways could
also delineate new targets for manipulation of their activities as an
option for treatment.
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